New proteasome inhibitors in the treatment of multiple myeloma
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2019/01/01
-
Indian UGC (journal)
-
Refrences56
-
Citations25
-
Vania Tietsche de Moraes Hungria
-
Edvan de Queiroz Crusoé
-
Rosane Isabel Bittencourt
-
Angelo Maiolino
-
Roberto José Pessoa Magalhães
-
Jairo do Nascimento Sobrinho
-
Jorge Vaz Pinto
-
Ricardo Coutinho Fortes
-
Eloisa de Sá Moreira
-
Paula Yurie Tanaka
Cite
Hungria, Vania Tietsche de Moraes, et al. “New Proteasome Inhibitors in the Treatment of Multiple Myeloma”. Hematology, Transfusion and Cell Therapy, vol. 41, no. 1, 2019, pp. 76-83, https://doi.org/10.1016/j.htct.2018.07.003.
Hungria, V. T. de M., Crusoé, E. de Q., Bittencourt, R. I., Maiolino, A., Magalhães, R. J. P., Sobrinho, J. do N., Pinto, J. V., Fortes, R. C., Moreira, E. de S., & Tanaka, P. Y. (2019). New proteasome inhibitors in the treatment of multiple myeloma. Hematology, Transfusion and Cell Therapy, 41(1), 76-83. https://doi.org/10.1016/j.htct.2018.07.003
Hungria VT de M, Crusoé E de Q, Bittencourt RI, Maiolino A, Magalhães RJP, Sobrinho J do N, et al. New proteasome inhibitors in the treatment of multiple myeloma. Hematology, Transfusion and Cell Therapy. 2019;41(1):76-83.
Journal Categories
Medicine
Internal medicine
Neoplasms
Tumors
Oncology
Including cancer and carcinogens
Medicine
Internal medicine
Specialties of internal medicine
Diseases of the blood and blood-forming organs
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial | 2017 | |||
Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions | British Journal of Haematology |
| 36 | 2017 |
How I treat myeloma with new agents | Blood Journal |
| 53 | 2017 |
| Observational study of multiple myeloma in Latin America | Annals of Hematology |
| 23 | 2017 |
| Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma | Seminars in Oncology Nursing |
| 8 | 2017 |
Refrences Analysis
The category
Medicine: Medicine (General) 34
is the most frequently represented among the references in this article. It primarily includes studies from New England Journal of Medicine The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Identification and in-vitro analysis of potential proteasome inhibitors targeting PSMβ5 for multiple myeloma | Biomedicine & Pharmacotherapy |
| 4 | 2023 |
| Current approach to Waldenström macroglobulinemia | Blood Reviews |
| 2023 | |
| Proteasome inhibitors as anticancer agents | Expert Opinion on Therapeutic Patents |
| 1 | 2023 |
Design and synthesis of amino-substituted N-arylpiperidinyl-based inhibitors of the (immuno)proteasome | Acta Pharmaceutica |
| 2023 | |
BTK Inhibitors and Other Targeted Therapies in Waldenström Macroglobulinemia | Hemato |
| 1 | 2023 |
Citations Analysis
The category
Medicine: Medicine (General) 11
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled The proteasome as a target for protozoan parasites and was published in 2019. The most recent citation comes from a 2023 study titled Proteasome inhibitors as anticancer agents. This article reached its peak citation in 2021, with 9 citations. It has been cited in 21 different journals, 33% of which are open access. Among related journals, the International Journal of Molecular Sciences cited this research the most, with 3 citations. The chart below illustrates the annual citation trends for this article.